Notice of first launch, interruption or termination of supply of a human drug
 DateHolderCodeDrug ▼Date fromSubject
 21.5.2019Pfizer Europe MA EEIG (PFI-BE-3)94959ACCUPRO 10 (tbl flm 30x10 mg (blis.Al/PA/Al/PVC))21.5.2019O
 24.6.2019Pfizer Europe MA EEIG (PFI-BE-3)94959ACCUPRO 10 (tbl flm 30x10 mg (blis.Al/PA/Al/PVC))24.6.2019R
 6.4.2020Pfizer Europe MA EEIG (PFI-BE-3)94959ACCUPRO 10 (tbl flm 30x10 mg (blis.Al/PA/Al/PVC))7.4.2020O
 13.4.2022Pfizer Europe MA EEIG (PFI-BE-3)94959ACCUPRO 10 (tbl flm 30x10 mg (blis.Al/PA/Al/PVC))13.4.2022R
 7.8.2019Pfizer Europe MA EEIG (PFI-BE-3)94960ACCUPRO 20 (tbl flm 30x20 mg (blis.Al/PA/Al/PVC))8.8.2019O
 24.2.2020Pfizer Europe MA EEIG (PFI-BE-3)94960ACCUPRO 20 (tbl flm 30x20 mg (blis.Al/PA/Al/PVC))28.2.2020O
 13.4.2022Pfizer Europe MA EEIG (PFI-BE-3)94960ACCUPRO 20 (tbl flm 30x20 mg (blis.Al/PA/Al/PVC))13.4.2022R
 20.12.2019Pfizer Europe MA EEIG (PFI-BE-3)94960ACCUPRO 20 (tbl flm 30x20 mg (blis.Al/PA/Al/PVC))20.12.2019R
 11.3.2020Pfizer Europe MA EEIG (PFI-BE-3)94958ACCUPRO 5 (tbl flm 30x5 mg (blis.Al/PA/Al/PVC))13.3.2020O
 30.4.2019Pfizer Europe MA EEIG (PFI-BE-3)94958ACCUPRO 5 (tbl flm 30x5 mg (blis.Al/PA/Al/PVC))30.4.2019R
 13.4.2022Pfizer Europe MA EEIG (PFI-BE-3)94958ACCUPRO 5 (tbl flm 30x5 mg (blis.Al/PA/Al/PVC))13.4.2022R
 17.7.2019Pfizer Europe MA EEIG (PFI-BE-3)94958ACCUPRO 5 (tbl flm 30x5 mg (blis.Al/PA/Al/PVC))18.7.2019O
 11.10.2019Pfizer Europe MA EEIG (PFI-BE-3)94958ACCUPRO 5 (tbl flm 30x5 mg (blis.Al/PA/Al/PVC))16.10.2019R
 11.3.2020Pfizer Europe MA EEIG (PFI-BE-3)94958ACCUPRO 5 (tbl flm 30x5 mg (blis.Al/PA/Al/PVC))13.3.2020O
 22.1.2020Pfizer Europe MA EEIG (PFI-BE-3)27551ACCUZIDE 10 (tbl flm 100x10 mg/12,5 mg (blis. PVC/PVDC/Al))22.1.2020O

Subject means:
U-Placement of medicine to Slovakian market, R-Discontinuation of medicine supply to Slovakian market,
O-Resumption of medicine supply to Slovakian market, Z-Cancelation of medicine supply to Slovakian market


Date from
From
To